Tobacco Education and Lung Health Study (TEAL)
Recruiting
Phase 3
Interventional Study
Smoking Cessation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 – 80
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,188 (estimated)
- Sponsor
- Georgetown University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinence from cigarettes.
Secondary Objectives 1) To evaluate reach and engagement overall and by subgroup (e.g., race and ethnicity, underinsured, readiness to quit).…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* eligible for a screening or diagnostic scan,
* USPSTF eligibility criteria (50-80 years old and \>20-pack years);
* currently smoking cigarettes (\>1 in the past 30 days);
* English speaking;
* able to provide meaningful consent.
Exclusion Criteria:
* prior lung cancer,
* he…
Contacts